Jeremiah Johnson, executive director of PrEP4All, an organization committed to HIV prevention and care, talks about the ...

Rising Medicare exit rates among physicians, especially primary care, highlight growing dissatisfaction and administrative ...

Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to ...

The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus ...

In this interview, Sarah Morris, chief product officer of Audere, explains why they chose to focus on women and young girls ...

Health policy researcher Geoffrey Joyce argues that only delinking compensation from the list price of a drug will lower drug ...

Replimune's RP1 treatment for advanced melanoma faces FDA rejection due to trial design issues, despite promising results ...

Humana has released details about additional, upcoming organizational improvements to encourage a faster prior authorization ...

This biosimilars market report focuses on rising market complexity and recent activity, including two new approvals and four ...

BioMarin's Roctavian gene therapy shows long-term effectiveness in treating severe hemophilia A, reducing bleeding and ...

The Vision Center at Children’s Hospital Los Angeles is developing a protocol for a phase 1 clinical trial for the first gene ...

Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators ...